Our Mission

Over 30 million Americans have tried GLP-1 medications like semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound). More than half say these medications are hard to afford.

The problem? Every existing "comparison" site is actually an affiliate-driven listicle that ranks whoever pays the most. There's no neutral, data-driven tool to help consumers compare providers on price, legitimacy, and transparency.

GLP123.ai changes that.

We compare telehealth providers selling compounded semaglutide and tirzepatide - and we're adding more all the time. We show real pricing - medication costs, membership fees, hidden fees, and the true total monthly cost. We don't rank providers based on who pays us. We rank them on data.

Our Principles

• 1. Neutral. We don't accept payment from providers to influence rankings. If we add affiliate links, they'll be clearly labeled and won't affect sort order.
• 2. Transparent. We show our data sources and last-verified dates. If we don't know something, we say so.
• 3. Consumer-first. This tool exists to help people find affordable medication, not to sell ads.

Important Disclaimers